Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XoGlo Pro in Adults With Mild to Moderate COVID-19
NCT07664696Phase 2Not yet recruiting
- Sponsor
- Kimera Labs
- Start
- Jan 2027
- Primary completion
- Jun 2028
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Kimera Labs. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 180 days. Planned start Jan 2027; status: not yet recruiting.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07664696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07664696.